Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Biochemical study of ACTA2 mutations leading to multi-systemic smooth muscle dysfunction syndrome

FY 2023-24

Summary
Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare genetic disorder characterized by dysfunction in smooth muscle cells (SMCs) throughout the body, leading to a wide range of clinical manifestations. MSMDS is associated with mutations in the Actin alpha 2 (ACTA2) gene occurring at multiple residues. Non-synonymous mutations at R179C/G/H/L/S lead to the most severe form of the syndrome, causing dysfunction in vascular, gastrointestinal (GI), and cerebrovascular diseases. Mutations at R258H, cause only vascular symptoms and at R39C/H, lead to GI symptoms and may involve some vascular issues. Currently, there is no available data explaining how various ACTA2 gene variations lead to the diverse effects of MSMDS. In this project, we aim to take advantage of the distinct phenotypic outcomes associated with each ACTA2 mutation to unravel the underlying molecular mechanisms and focus on understanding the network of ACTA2 protein interactions at a disease-state and homeostasis. We will characterize WT and mutant ACTA2 protein via protein-protein interactions with BioID2 protocol and downstream mass spectrometry. To confirm ACTA2 interactions, co-immunoprecipitation and immunofluorescence experiments will validate the identified proteins of interest. Lastly to determine ACTA2’s function interactions, we will overexpress ACTA2 in SMCs to biochemically validate ACTA2 protein networks. We speculate that the different symptoms in MSMDS are caused by how mutations in the ACTA2 gene affect its interactions with other proteins. By carefully comparing how the normal ACTA2 protein interacts with other proteins versus how mutant ACTA2 proteins do, to uncover specific effects caused by mutations and understand why certain symptoms occur in different parts of the body.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506179
Name
Rezvan Samana A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Biochemical study of ACTA2 mutations leading to multi-systemic smooth muscle dysfunction syndrome
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Actin Alpha 2 (Acta2) - Smooth Muscle; Cardiovascular Disease; Moyamoya Disease; Multisystemic Smooth Muscle Dysfunction Syndrome (Msmds); Protein-Protein Interactions; Proteomics; R179h Mutation; R258c/H Mutation; Stroke; Thoracic Aortic Aneurysm
Abstract
Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare genetic disorder characterized by dysfunction in smooth muscle cells (SMCs) throughout the body, leading to a wide range of clinical manifestations. MSMDS is associated with mutations in the Actin alpha 2 (ACTA2) gene occurring at multiple residues. Non-synonymous mutations at R179C/G/H/L/S lead to the most severe form of the syndrome, causing dysfunction in vascular, gastrointestinal (GI), and cerebrovascular diseases. Mutations at R258H, cause only vascular symptoms and at R39C/H, lead to GI symptoms and may involve some vascular issues. Currently, there is no available data explaining how various ACTA2 gene variations lead to the diverse effects of MSMDS. In this project, we aim to take advantage of the distinct phenotypic outcomes associated with each ACTA2 mutation to unravel the underlying molecular mechanisms and focus on understanding the network of ACTA2 protein interactions at a disease-state and homeostasis. We will characterize WT and mutant ACTA2 protein via protein-protein interactions with BioID2 protocol and downstream mass spectrometry. To confirm ACTA2 interactions, co-immunoprecipitation and immunofluorescence experiments will validate the identified proteins of interest. Lastly to determine ACTA2’s function interactions, we will overexpress ACTA2 in SMCs to biochemically validate ACTA2 protein networks. We speculate that the different symptoms in MSMDS are caused by how mutations in the ACTA2 gene affect its interactions with other proteins. By carefully comparing how the normal ACTA2 protein interacts with other proteins versus how mutant ACTA2 proteins do, to uncover specific effects caused by mutations and understand why certain symptoms occur in different parts of the body.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rezvan, Samana A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~